PaxMedica (PXMD) Stock Price, News & Analysis

Company Overview

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.11
• 52-Week Range: $0.03 to $1.19
• Volume: 19 shs
• Average Volume: 49,782 shs
• Market Capitalization: $350,610.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXMD Stock Analysis - Frequently Asked Questions

How have PXMD shares performed this year?

PaxMedica's stock was trading at $0.0617 at the start of the year. Since then, PXMD shares have decreased by 49.8% and is now trading at $0.0310.
View the best growth stocks for 2025 here.

When did PaxMedica's stock split?

Shares of PaxMedica reverse split before market open on Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did PaxMedica IPO?

PaxMedica (PXMD) raised $9 million in an IPO on Friday, August 26th 2022. The company issued 1,600,000 shares at $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO.

How do I buy shares of PaxMedica?

Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PaxMedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PaxMedica investors own include Pfizer (PFE), PayPal (PYPL), Oracle (ORCL), Arista Networks (ANET), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Today: 1/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PXMD
• CUSIP: N/A
• CIK: 1811623
• Web: www.paxmedica.com
• Phone: 914-987-2876
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,290,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,167.89%
• Return on Assets: -560.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 11,310,000
• Free Float: 11,199,000
• Market Cap: $350,610.00
• Optionable: Not Optionable
• Beta: -0.40